

## Prior Authorization DRUG Guidelines

### **SUCRAID (Sacrosidase)**

Effective Date: 1/28/14

Date Developed: 1/28/14 by Catherine Sanders, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20,  
2/2/21, 8/3/21, 2/1/22, 1/31/23, 2/13/24

Sacrosidase is a naturally-occurring gastrointestinal enzyme derived from baker's yeast (*Saccharomyces cerevisiae*) which breaks down the disaccharide sucrose to its monosaccharide components. Hydrolysis is necessary to allow absorption of these nutrients.

#### **Pre-Authorization Criteria:**

**Congenital sucrase-isomaltase deficiency:** Oral replacement therapy in sucrase deficiency, as seen in congenital sucrase-isomaltase deficiency (CSID)

**NOTE:** VCHCP requires that Sacrosidase be prescribed by a physician specializing in the condition being treated.

**NOTE:** Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to <http://www.sucraid.net/how-to-order-sucraid> or call 1-866-740-2743.

#### **Dosing: Adult:**

**Congenital sucrase-isomaltase deficiency (CSID):** Oral: 17,000 units (2 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula. Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack.

#### **Dosing: Pediatric:**

**Congenital sucrase-isomaltase deficiency (CSID):**

**Infants ≥5 months and Children ≤15 kg: Oral:** 8500 units (1 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula.

Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack.

**Children >15 kg and Adolescents:** Refer to adult dosing.

**NOTE:** Dilute dose in 2-4 oz of cold or room temperature water, milk, or formula; avoid fruit juices or warm or hot food/liquids (may lower potency).

**Dosage Forms: U.S.:**

Solution, Oral: Sucraid: 8500 units/mL (118 mL) [contains papain; 50% glycerol]

**Adverse Reactions:**

Headache, insomnia, nervousness, dehydration, abdominal pain, constipation, diarrhea, nausea, vomiting.

**Contraindications:**

Hypersensitivity to yeast, yeast products, glycerin (glycerol) or papain

**References:**

1. Blanco C, Carrillo T, Castillo R, et al, "Latex Allergy: Clinical Features and Cross-Reactivity With Fruits," *Ann Allergy*, 1994, 73(4):309-14. [PubMed [7943998](#)]
2. Focke M, Hemmer W, Wohrl S, et al, "Cross-reactivity Between *Ficus benjamina* Latex and Fig Fruit in Patients With Clinical Fig Allergy," *Clin Exp Allergy*, 2003, 33(7):971-7. [PubMed [12859455](#)]
3. Freye HB, "Papain Anaphylaxis: A Case Report," *Allergy Proc*, 1988, 9(5):571-4. [PubMed [3234762](#)]
4. Isola S, Ricciardi L, Saitta S, et al, "Latex Allergy and Fruit Cross-Reaction in Subjects Who Are Nonatopic," *Allergy Asthma Proc*, 2003, 24(3):193-7. [PubMed [12866323](#)]
5. Treem WR, McAdams L, Stanford L, et al, "Sacrosidase Therapy for Congenital Sucrose-Isomaltase Deficiency," *J Pediatr Gastroenterol Nutr*, 1999, 28(2):137-42. [PubMed [9932843](#)]
6. Sucraid (sacrosidase) oral solution [prescribing information]. Vero Beach, FL: QOL Medical, LLC; September 2018.

**Revision History:**

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/2/21

Date Reviewed/Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 8/3/21  
 Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 2/1/22  
 Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 1/31/23  
 Date Reviewed/No Updates: 2/13/24 by H. Taekman, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 2/13/24.

<b>Revision Date</b>	<b>Content Revised (Yes/No)</b>	<b>Contributors</b>	<b>Review/Revision Notes</b>
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Formatting changes
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review